1.	Phase III Randomized, Double-Blind Study of 5-FU/SMS 201-995 pa LAR vs 5-FU/Placebo for Unresectable Stage II or Stage III/IV Pancreatic Cancer (Summary Last Modified 10/97) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SANDOZ-SMSM-304-E-00, NCI-V95-0798
2.	Phase III Randomized Double-Blind Study of Tamoxifen/Octreotide Pamoate vs Tamoxifen/Placebo in Women with Locally Recurrent or Metastatic Breast Cancer (Summary Last Modified 12/98) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SANDOZ-SMST-302, NCI-V96-0934
3.	Phase III Study of the Addition of Octreotide Pamoate (SMS 201-995 pa LAR) to Tamoxifen Alone or to Tamoxifen and Chemotherapy in Women With Axillary Node Negative, Estrogen Receptor Positive, Primary Invasive Breast Cancer Phase: Phase III Type: Treatment Status: Completed Age: Not specified Sponsor: NCI Protocol IDs: NSABP-B-29, NCT00002967
4.	Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CSMS995ADE05, NCT00171873
5.	Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: CSMS995AIC04, NCT00582426
6.	Phase I Study of Octreotide Pamoate With or Without Tamoxifen in Patients With Osteosarcoma (Summary Last Modified 12/2000) Phase: Phase I Type: Treatment Status: Completed Age: 25 and under (at time of diagnosis) Sponsor: NCI Protocol IDs: NCI-95-C-0119I, NCI-T96-0047N, T96-0047